GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Savient Pharmaceuticals Inc (SVNTQ) [hlAlert]

Rating:
Underperform
SVNT
down 55.64 %

Savient Pharmaceuticals Inc (SVNT) downgraded to Underperform by Cowen & Co

Posted on: Monday,  Oct 27, 2008  9:25 AM ET by Cowen & Co

Cowen & Co rated Underperform Savient Pharmaceuticals Inc (OTCBB: SVNTQ) on 10/27/2008. Previously Cowen & Co rated Buy Savient Pharmaceuticals Inc (OTCBB: SVNTQ)
on 09/21/2007., when the stock price was $14.09. Since then, Savient Pharmaceuticals Inc has lost 55.64% as of 10/27/2008's recent price of $6.25.
If you would have followed the previous Cowen & Co's recommendation on SVNTQ, you would have lost 55.64% of your investment in 402 days.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and marketing pharmaceutical products that target unmet medical needs in both niche and specialty markets. During the year ended December 31, 2008, the Company developed KRYSTEXXA (pegloticase), a therapy for patients with treatment-failure gout (TFG) to control hyperuricemia and to manage the signs and symptoms of gout, including the improvement of tophi, improvement in chronic pain, improved physical functioning and decreased frequency of flares. The Company sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. The Company distributes the branded version of oxandrolone in the United States under the name Oxandrin and its authorized generic version of oxandrolone through an agreement with Watson Pharma, Inc. (Watson).

Cowen and Company’s culture is rooted in the traditions of the research boutiques that once dominated the investment research landscape. Our primary focus is on two products: 1. Proprietary information flow, and 2. Good investment ideas We achieve the first objective with a combination of extensive primary research work, organized survey activity, and access to industry experts (i.e., opinion leaders in medicine, technology, and consumer industries). We believe that the best investment idea is a “Correct Non-Consensus Conclusion,” and a considerable amount of our energy is devoted to this pursuit. We spend as little time as possible on traditional maintenance research products.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/27/2008 9:25 AM Sell
None
6.25
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/21/2007 9:25 AM Buy
None
14.09

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy